Paper Review — Verify Claims Fast

1) Strengths: coherent framework + biologically grounded risk decomposition

• Coherent systems framing: the three risk domains and three strategy buckets create a readable decision logic that aligns with the multifactorial etiology described across HBV/HCV/aflatoxin and metabolic drivers. Framework coherence
• Uses multiple evidence types: the review cites cohorts, meta-analyses, GWAS/PRS work, and biomarker developments (e.g., cell-free DNA methylation signatures) while also discussing practical limitations. Evidence-type diversity in review
• Explicit bias-awareness: it states narrative-synthesis limits, selection bias risk, and the need for external validation/portability testing. Bias-awareness by author

2) Key scientific gaps & skeptical “unknown unknowns”

• Risk-tier thresholds and end-to-end effectiveness are not established: The review describes surveillance intensity changes (e.g., ultrasound ± AFP every 6 months baseline, intensified when risk thresholds/biomarkers exceed cutoffs), but it also notes that values in its decision-flow figure are “illustrative placeholders,” meaning the operational cutpoints are not empirically validated inside this paper. Placeholders in decision pathway
• Biomarker “surrogates” vs actual HCC endpoints: For “green” chemoprevention, much of the described evidence emphasizes intermediate biomarkers (e.g., urinary aflatoxin-DNA adducts). That can be biologically persuasive, but it is not the same as proving durable reduction in incident HCC across populations. Biomarker-level support
• Portability risk for PRS-based stratification: The review discusses PRS risk stratification and cross-population tailoring, but PRS transfer across ancestries can be poor and can worsen disparities without recalibration. PRS portability concerns
• Heterogeneity & confounding in exposure epidemiology: Environmental exposures (pollution/occupational toxins) are notoriously hard to measure precisely, and associations may be confounded by correlated behaviors and access to healthcare. The review itself states limited epidemiologic evidence for several agents. Environmental evidence insufficiency

3) What would most strongly falsify or force revision?

• Prospective, multi-ancestry validation failure: If integrated risk-tier surveillance (biomarker + PRS + fibrosis scores + clinical features) doesn’t improve early detection or outcomes compared with standard surveillance, the central “precision prevention” operational claim would be weakened. The review points to the need for prospective validation and external validation. Need for prospective/external validation
• Disproportionate performance drop in non-modeled settings: If biomarker algorithms (e.g., multi-marker serology frameworks) show major sensitivity/specificity drops in different prevalence, imaging capability, or comorbidity structures, the portability assumption fails. The review explicitly flags portability and performance issues. Performance variability risk
• “Surrogate endpoint” to “HCC outcome” mismatch: If diet/plant-based interventions repeatedly fail to reduce incidence or mortality despite improving intermediate biomarkers, the causal link inferred through surrogates would need re-evaluation. This is consistent with the review’s own caution about standardization, bioavailability, and long-term safety uncertainties. Long-term uncertainty for green agents

4) Practical user takeaway (scientifically, not prescriptively)

If you want to operationalize this review into a research plan, the critical next step is not “more agents,” but more end-to-end prospective validation of a full pipeline: (i) risk-tier assignment, (ii) surveillance trigger thresholds, and (iii) whether this improves HCC incidence/early stage detection and doesn’t degrade efficiency/accuracy in underrepresented populations. The review repeatedly points to these validation needs and portability challenges. Key next-step: validation pipeline